FY2026 EPS Estimate for Gossamer Bio Boosted by Analyst

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Gossamer Bio in a report released on Friday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($14.09) per share for the year, up from their prior forecast of ($21.00). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($27.13) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($1.66) EPS, Q2 2027 earnings at ($1.69) EPS, Q3 2027 earnings at ($0.97) EPS, Q4 2027 earnings at ($0.99) EPS, FY2027 earnings at ($5.12) EPS, FY2028 earnings at ($4.15) EPS and FY2029 earnings at ($1.51) EPS.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($7.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.79) by ($3.57). The firm had revenue of $38.43 million during the quarter, compared to the consensus estimate of $12.16 million.

Other equities research analysts have also recently issued research reports about the company. Chardan Capital restated a “buy” rating on shares of Gossamer Bio in a research note on Monday, October 26th. Weiss Ratings cut shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Wedbush dropped their price objective on shares of Gossamer Bio to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 11th. Finally, Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research note on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $246.40.

View Our Latest Stock Report on GOSS

Gossamer Bio Trading Up 0.1%

Shares of NASDAQ GOSS opened at $10.98 on Tuesday. The company has a market capitalization of $67.15 million, a P/E ratio of -0.24 and a beta of 2.28. Gossamer Bio has a 12 month low of $8.29 and a 12 month high of $309.60. The stock has a 50 day moving average of $10.50 and a 200-day moving average of $31.97.

Hedge Funds Weigh In On Gossamer Bio

Institutional investors and hedge funds have recently made changes to their positions in the company. Corient Private Wealth LP lifted its holdings in Gossamer Bio by 41.3% during the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after purchasing an additional 1,647,315 shares during the last quarter. Bank of America Corp DE acquired a new position in Gossamer Bio in the 2nd quarter valued at $65,000. Hsbc Holdings PLC grew its holdings in Gossamer Bio by 1,289.4% in the 2nd quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock valued at $267,000 after buying an additional 1,469,175 shares in the last quarter. Kalehua Capital Management LLC bought a new position in Gossamer Bio during the 1st quarter worth $3,363,000. Finally, Hhlr Advisors LTD. bought a new position in Gossamer Bio during the 2nd quarter worth $819,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio News Summary

Investors following GOSS have been watching these news items:

  • Positive Sentiment: HC Wainwright improved estimates for FY2026 and FY2027, with FY2026 projected loss narrowing to $14.09 per share from $21.00 and FY2027 to $5.12 from $5.64. It also raised estimates for Q1–Q4 2027, with smaller projected losses, and maintained its “Buy” rating. Gossamer Bio analyst estimates
  • Neutral Sentiment: The analyst’s projections still imply substantial losses, including a $27.13-per-share consensus loss for the current fiscal year; the estimates alone do not indicate a change in Gossamer Bio’s operating outlook. Gossamer Bio financial information
  • Negative Sentiment: Not all revisions were favorable: HC Wainwright widened its projected Q4 2026 loss to $2.02 per share from $1.95, trimmed FY2029 to a $1.51 loss from $1.48, and lowered its FY2030 profit forecast to $2.54 from $2.60. Gossamer Bio FY2030 Earnings Forecast Cut by HC Wainwright

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company develops medicines for serious diseases, with a focus on pulmonary vascular conditions. Its lead candidate is seralutinib, an inhaled investigational therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Seralutinib is not an approved medicine. Gossamer has partnered with Chiesi Group to advance its development.

Recommended Stories

Earnings History and Estimates for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.